Patient demographic and clinical characteristics
| Characteristic . | Number . | % . |
|---|---|---|
| Median age 61 y (range, 29-85) | 30 | 100 |
| Sex | ||
| Female | 12 | 40 |
| Male | 18 | 60 |
| Disease stage at study entry | ||
| I/II | 3 | 10 |
| III/IV | 27 | 90 |
| Histology | ||
| Small lymphocytic lymphoma | 2 | 7 |
| Follicular | 25 | 83 |
| Transformed | 3 | 10 |
| Extranodal disease, no. of sites | ||
| 0, 1 | 24 | 80 |
| 2 or more | 6 | 20 |
| Bone marrow involvement, % | ||
| 0 to less than 5 | 10 | 33 |
| 5 to 20 | 12 | 40 |
| More than 20 to less than 25 | 8 | 27 |
| WHO performance status | ||
| 0, 1 | 29 | 97 |
| 2 | 1 | 3 |
| Splenomegaly | 7 | 23 |
| IPI risk group | ||
| Low | 10 | 33 |
| Low/intermediate | 10 | 33 |
| Intermediate/high | 6 | 20 |
| High | 2 | 7 |
| Unknown | 2 | 7 |
| Baseline LDH | ||
| Normal/low | 17 | 57 |
| High | 11 | 37 |
| Unknown | 2 | 6 |
| Prior chemotherapy | 30 | 100 |
| Median 2 (range, 1-9) | ||
| Resistant* to 1 or more | 19 | 63 |
| Resistant* to last | 14 | 47 |
| Prior chemotherapy type | ||
| Alkylator ± prednisone | 12 | 40 |
| Purine analogs | 8 | 27 |
| Steroids | 9 | 30 |
| CVP or COP | 8 | 27 |
| CHOP | 12 | 40 |
| Other aggressive | 13 | 43 |
| Prior radiotherapy | 5 | 17 |
| Bulky disease, cm | ||
| Less than 5 | 16 | 53 |
| 5 to less than 7 | 9 | 30 |
| 7 to less than 10 | 3 | 10 |
| 10 or more | 2 | 7 |
| Characteristic . | Number . | % . |
|---|---|---|
| Median age 61 y (range, 29-85) | 30 | 100 |
| Sex | ||
| Female | 12 | 40 |
| Male | 18 | 60 |
| Disease stage at study entry | ||
| I/II | 3 | 10 |
| III/IV | 27 | 90 |
| Histology | ||
| Small lymphocytic lymphoma | 2 | 7 |
| Follicular | 25 | 83 |
| Transformed | 3 | 10 |
| Extranodal disease, no. of sites | ||
| 0, 1 | 24 | 80 |
| 2 or more | 6 | 20 |
| Bone marrow involvement, % | ||
| 0 to less than 5 | 10 | 33 |
| 5 to 20 | 12 | 40 |
| More than 20 to less than 25 | 8 | 27 |
| WHO performance status | ||
| 0, 1 | 29 | 97 |
| 2 | 1 | 3 |
| Splenomegaly | 7 | 23 |
| IPI risk group | ||
| Low | 10 | 33 |
| Low/intermediate | 10 | 33 |
| Intermediate/high | 6 | 20 |
| High | 2 | 7 |
| Unknown | 2 | 7 |
| Baseline LDH | ||
| Normal/low | 17 | 57 |
| High | 11 | 37 |
| Unknown | 2 | 6 |
| Prior chemotherapy | 30 | 100 |
| Median 2 (range, 1-9) | ||
| Resistant* to 1 or more | 19 | 63 |
| Resistant* to last | 14 | 47 |
| Prior chemotherapy type | ||
| Alkylator ± prednisone | 12 | 40 |
| Purine analogs | 8 | 27 |
| Steroids | 9 | 30 |
| CVP or COP | 8 | 27 |
| CHOP | 12 | 40 |
| Other aggressive | 13 | 43 |
| Prior radiotherapy | 5 | 17 |
| Bulky disease, cm | ||
| Less than 5 | 16 | 53 |
| 5 to less than 7 | 9 | 30 |
| 7 to less than 10 | 3 | 10 |
| 10 or more | 2 | 7 |
WHO indicates World Health Organization; IPI, International Prognostic Index; LDH, lactic dehydrogenase; CVP, cyclophosphamide, vincristine, prednisone; COP, cyclophosphamide, vincristine, prednisone; and CHOP, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone.
Resistance is defined as no response (complete response or partial response) or disease progression within 6 months.